Regeneron Unveils $500M Biotech-Focused Venture Capital Fund

1. Regeneron, a biotechnology company, has launched a new venture capital fund with a focus on biotech investments.
2. The fund is allocated $500 million to support innovation and growth in the biotech sector.
3. The fund's launch aims to foster the development of new technologies and therapies in the biotech industry.

Please note that the search results also include information about AstraZeneca, which is not directly related to Regeneron's venture capital fund announcement.